<cite id="njbft"></cite><var id="njbft"><video id="njbft"></video></var>
<var id="njbft"></var>
<listing id="njbft"></listing>
<cite id="njbft"></cite>
<menuitem id="njbft"><strike id="njbft"></strike></menuitem><var id="njbft"></var> <var id="njbft"><strike id="njbft"><thead id="njbft"></thead></strike></var><var id="njbft"><video id="njbft"></video></var>
<cite id="njbft"><video id="njbft"><menuitem id="njbft"></menuitem></video></cite>
新闻资讯
科思
/
/
/
Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:25
  • 访问量:

【概要描述】To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

【概要描述】To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

  • 分类:学术论文
  • 作者:
  • 来源:
  • 发布时间:2016-08-12 09:25
  • 访问量:
详情

  PURPOSE: To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

  MATERIALS AND METHODS: Between June 2009 and April 2011, 35 de novo SFA lesions were treated with 43 biodegradable stents. This nonrandomized, retrospective, single-center study included patients with moderate or severe claudication, lower-limb rest pain, or ischemic ulceration restricted to the toes; symptoms were classified as Rutherford category 2 (48.6%), 3 (37.1%), 4 (8.6%), or 5 (5.7%). The population included 28 men and had a mean age of 71 years (range, 51-81 y). Follow-up included clinical examination and color-flow duplex imaging. Mean follow-up was 38.3 months (range, 30-58 mo).

  RESULTS: Technical success was reported in all patients (100%). There were no intraoperative or immediate (< 30 d) complications.. During follow-up, one in-stent occlusion and seven in-stent restenoses occurred, all of which were successfully treated with percutaneous transluminal angioplasty. Primary and secondary patency rates were 77.1% and 97.1% at 24 and 36 months, respectively. No stent recoil or stent fracture was encountered. Late follow-up (> 12 mo) by ultrasound confirmed total reabsorption of the stent structures. Clinical improvement (ie, an upward shift of at least two Rutherford categories) was achieved in all 35 patients.

  CONCLUSIONS: Midterm results for biodegradable PLLA stents for atherosclerotic SFA lesions were associated with high technical success and secondary patency rates, without stent recoil and vessel remodeling.

阿迈特“易泊EZPo?”支架定位系统在河南省胸科医院成功完成上市后临床应用
2023 08-12

阿迈特“易泊EZPo?”支架定位系统在河南省胸科医院成功完成上市后临床应用

北京阿迈特的颅内球囊扩张导管产品获批上市
2023 08-10

北京阿迈特的颅内球囊扩张导管产品获批上市

喜报—北京阿迈特医疗器械有限公司取得国医械华光认证GB/T 42061-2022 idt ISO13485:2016医疗器械质量管理体系认证证书
2023 07-21

喜报—北京阿迈特医疗器械有限公司取得国医械华光认证GB/T 42061-2022 idt ISO13485:2016医疗器械质量管理体系认证证书

公司信息

北京阿迈特医疗器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             邮箱:amt@ametcorp.com

联系我们

地址:北京市大兴区永旺西路26号院中关村医疗器械园11号楼

电话:010-6297-7955             

邮箱:amt@ametcorp.com

久久99精品国产自在现线小黄鸭,亚洲国产精品一区二区玖玖爱,亚洲日韩精品无码av海量国产精,日产精品久久久1区2区_影院 久久久久久久久亚洲精品_久久久一区二区人妻av_国产午夜影院黄色片_日韩一区二区在线视频 精品久久久久久久中文字幕|十八禁无码免费网站|A片免费一级无码|人妻被按摩到潮喷中文字幕 色欲天天_久久精彩_精品日本一区二区三区在线观看_精品久久久久无码人妻中文字幕 欧美性战a久久久久久_91精品无码一区_欧美oumeisetu_久久国产乱子伦精 久久久午夜视频,久久国产第一区二区三区日韩精品,欧美综合精品激情久久久久,国内精品一区二区